Demyelinating Syndromes in Systemic Lupus Erythematosus: Data From the "Attikon" Lupus Cohort.
central nervous system
demyelination
multiple sclerosis
outcome demyelination in systemic lupus erythematosus
systemic lupus erythematosus
Journal
Frontiers in neurology
ISSN: 1664-2295
Titre abrégé: Front Neurol
Pays: Switzerland
ID NLM: 101546899
Informations de publication
Date de publication:
2022
2022
Historique:
received:
04
03
2022
accepted:
19
04
2022
entrez:
1
6
2022
pubmed:
2
6
2022
medline:
2
6
2022
Statut:
epublish
Résumé
The demyelinating syndromes of the central nervous system (CNS) that occur in the context of systemic lupus erythematosus (SLE) may represent a manifestation of neuropsychiatric lupus (NPSLE) or an overlap of SLE and multiple sclerosis (MS). The differential diagnosis between the two entities has important clinical implications because the therapeutic management differs. To characterize CNS demyelinating syndromes in a large SLE cohort as neuropsychiatric SLE (NPSLE) or SLE-MS overlap using a multidisciplinary approach and existing diagnostic (for MS) and classification criteria (for SLE). Patients from the "Attikon" lupus cohort ( We identified 26 patients with demyelinating syndromes (3.7%). Of them, 12 were diagnosed as primary SLE-demyelination (46.2%) and 14 as overlap SLE-MS (53.8%). The two groups did not differ with respect to rheumatologic and neurologic manifestations or autoantibodies. SLE patients with demyelination manifested mild extra-CNS disease mainly involving joints and skin, while severe non-CNS manifestations were rare. However, these patients were less likely to have elevated IgG index (OR 0.055 95% CI: 0.008-0.40) and positive oligoclonal bands (OR 0.09 95% CI: 0.014-0.56), as well as brain lesions in the spinal cord, infratentorial, periventricular, and juxtacortical regions. A single brain region was affected in 9 patients with SLE-demyelination (75%), while all patients with MS-SLE had multiple affected brain regions. MS-SLE overlap was associated with an increased likelihood of neurologic relapses (OR 18.2, 95% CI: 1.76-188), while SLE-demyelination patients were less likely to exhibit neurological deficits (EDSS >0) at the last follow-up visit (50 vs. 78.6% in SLE-MS, respectively). Demyelination in the context of SLE follows a more benign course compared to a frank SLE-MS overlap. Extension of follow-up will ascertain whether patients with SLE-demyelination evolve to MS, or this is a
Sections du résumé
Background
UNASSIGNED
The demyelinating syndromes of the central nervous system (CNS) that occur in the context of systemic lupus erythematosus (SLE) may represent a manifestation of neuropsychiatric lupus (NPSLE) or an overlap of SLE and multiple sclerosis (MS). The differential diagnosis between the two entities has important clinical implications because the therapeutic management differs.
Objectives
UNASSIGNED
To characterize CNS demyelinating syndromes in a large SLE cohort as neuropsychiatric SLE (NPSLE) or SLE-MS overlap using a multidisciplinary approach and existing diagnostic (for MS) and classification criteria (for SLE).
Methods
UNASSIGNED
Patients from the "Attikon" lupus cohort (
Results
UNASSIGNED
We identified 26 patients with demyelinating syndromes (3.7%). Of them, 12 were diagnosed as primary SLE-demyelination (46.2%) and 14 as overlap SLE-MS (53.8%). The two groups did not differ with respect to rheumatologic and neurologic manifestations or autoantibodies. SLE patients with demyelination manifested mild extra-CNS disease mainly involving joints and skin, while severe non-CNS manifestations were rare. However, these patients were less likely to have elevated IgG index (OR 0.055 95% CI: 0.008-0.40) and positive oligoclonal bands (OR 0.09 95% CI: 0.014-0.56), as well as brain lesions in the spinal cord, infratentorial, periventricular, and juxtacortical regions. A single brain region was affected in 9 patients with SLE-demyelination (75%), while all patients with MS-SLE had multiple affected brain regions. MS-SLE overlap was associated with an increased likelihood of neurologic relapses (OR 18.2, 95% CI: 1.76-188), while SLE-demyelination patients were less likely to exhibit neurological deficits (EDSS >0) at the last follow-up visit (50 vs. 78.6% in SLE-MS, respectively).
Conclusions
UNASSIGNED
Demyelination in the context of SLE follows a more benign course compared to a frank SLE-MS overlap. Extension of follow-up will ascertain whether patients with SLE-demyelination evolve to MS, or this is a
Identifiants
pubmed: 35645967
doi: 10.3389/fneur.2022.889613
pmc: PMC9131105
doi:
Types de publication
Journal Article
Langues
eng
Pagination
889613Informations de copyright
Copyright © 2022 Nikolopoulos, Kitsos, Papathanasiou, Kapsala, Garantziotis, Pieta, Gioti, Grivas, Voumvourakis, Boumpas and Fanouriakis.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Ann Rheum Dis. 2017 Dec;76(12):1992-2000
pubmed: 28780511
Arthritis Rheumatol. 2018 Feb;70(2):277-286
pubmed: 29073350
Arthritis Rheum. 1999 Apr;42(4):599-608
pubmed: 10211873
Best Pract Res Clin Rheumatol. 2013 Jun;27(3):405-24
pubmed: 24238696
NDT Plus. 2009 Dec;2(6):466-8
pubmed: 25949381
Lancet Neurol. 2016 Mar;15(3):292-303
pubmed: 26822746
Mult Scler. 2012 Jan;18(1):5-10
pubmed: 22146604
Mult Scler Relat Disord. 2020 Nov;46:102568
pubmed: 33296970
Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2610-5
pubmed: 12604793
Semin Arthritis Rheum. 2014 Jun;43(6):751-8
pubmed: 24332007
Lancet Neurol. 2018 Feb;17(2):162-173
pubmed: 29275977
Rheumatol Int. 2010 Feb;30(4):431-4
pubmed: 19826821
Lupus Sci Med. 2020 Jun;7(1):
pubmed: 32601172
Ann Neurol. 2011 Feb;69(2):292-302
pubmed: 21387374
Neurology. 1983 Nov;33(11):1444-52
pubmed: 6685237
Autoimmun Rev. 2017 Mar;16(3):244-252
pubmed: 28159705
Rheumatology (Oxford). 2021 Sep 1;60(9):4166-4174
pubmed: 33404657
Arch Neurol. 2008 Jan;65(1):78-83
pubmed: 18195142
Lupus. 2020 Apr;29(5):514-522
pubmed: 32106788
Mult Scler. 2019 Jul;25(8):1079-1085
pubmed: 30767720